OCX Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (24 Apr 2024 @ 14:01):

Stats
Today's Volume	27 339.00
Average Volume	56 538.00
Market Cap	19.70M
EPS	$0 ( 2024-03-29 )
Next earnings date	( $-0.820 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.710
ATR14	$0.0310 (1.28%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-11	Broadwood Partners, L.p.	Buy	2 420 000	Common Stock, no par value
2024-04-11	Broadwood Partners, L.p.	Buy	0	Common Stock, no par value
2024-04-15	Broadwood Partners, L.p.	Sell	0	Series A Convertible Preferred Stock
2024-04-11	Riggs Josh	Buy	3 390	Common Stock, no par value
2024-04-11	Arno Andrew	Buy	33 898	Common Stock, no par value

INSIDER POWER
37.38
Last 97 transactions
Buy: 36 875 696 \| Sell: 16 930 326

Volume Correlation

Long: -0.16 (neutral)

Short: -0.13 (neutral)

Signal:(50.248) Neutral

OncoCyte Corp Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

OncoCyte Corp Correlation - Currency/Commodity

0.36
( neutral )

-0.54
( weak negative )

0.00
( neutral )

-0.76
( moderate negative )

0.00
( neutral )

-0.78
( moderate negative )

OncoCyte Corp Financials

Annual	2023
Revenue:	$1.50M
Gross Profit:	$501 000 (33.33 %)
EPS:	$-3.63

Q3	2023
Revenue:	$429 000
Gross Profit:	$248 000 (57.81 %)
EPS:	$-0.790

Q2	2023
Revenue:	$463 000
Gross Profit:	$272 000 (58.75 %)
EPS:	$-20.60

Q1	2023
Revenue:	$297 000
Gross Profit:	$10 000.00 (3.37 %)
EPS:	$0.400

Financial Reports:

No articles found.

OncoCyte Corp

OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.